Benefits
Fatigue and low energy: Russian studies in patients diagnosed with an asthenic disorder
The largest study is a 28-centre Russian study published in Russian in 2010 by Voznesenskaia, Fokina and Iakhno, with data analysed on 728 patients who had psychoautonomic syndrome and asthenic disorders. Everyone in it received ladasten 50 to 100 mg a day for 28 days and there was no placebo group, so the reported 76.0 percent responder rate on CGI-Severity and 90.8 percent on CGI-Improvement cannot be separated from the natural course of the condition or from expectation. A separate randomised study from the drug's developer, the Zakusov Research Institute of Pharmacology, compared ladasten with placebo over 28 days in neurasthenia patients and reported a faster and larger fall in asthenic symptoms on the drug; it was published in Russian in 2009 and its abstract does not state how many people took part. Both were done in people carrying a clinical diagnosis, not in healthy adults, and neither has been repeated by any group outside Russia.
Stimulant and calming effects reported together in Russian patient trials
The Russian trials describe an unusual pairing: both a stimulant effect and an anxiety-reducing effect in the same patients, where amphetamine-type stimulants tend to raise anxiety and benzodiazepines tend to sedate. In the 2006 pilot the stimulant component predominated after a single dose. This pairing has only been reported in Russian-language studies from the institute that developed the drug, in patients with an asthenic disorder; the one placebo-controlled test in 10 healthy men found no change in subjective state. The explanation usually offered, that bromantane raises the brain's capacity to make dopamine rather than releasing stored dopamine, comes from gene-expression work in rat brain, and one of those rat studies attributes the first hours of the drug's action to increased dopamine release, so the contrast with amphetamine is not as clean as it is usually drawn.
Attention and performance: no gain measured in healthy, untired men
The one placebo-controlled test of bromantane alone on mental performance in healthy adults gave a single oral dose to 10 volunteers (Viatleva and colleagues, Voennyi Meditsinskii Zhurnal, 2000). It reported EEG changes the authors read as a mild rise in vigilance, and reduced tremor, but stated that bromantan did not alter subjective state or the principal components of operator performance in men who were not tired. An EEG pattern and a tremor reading are markers, not a measured improvement in attention or reaction time. No study in sleep-deprived people could be located.
Prohibited in competition, with no human performance trial behind it
Bromantan is on the World Anti-Doping Agency Prohibited List as a non-specified stimulant in class S6.A, meaning it is prohibited in competition. Russian athletes tested positive at the 1996 Atlanta Olympics, and the Court of Arbitration for Sport set aside the disqualifications of the two who had won bronze, the swimmer Andrei Korneev and the wrestler Zakhar Gouliev, because bromantan was not on the IOC prohibited list at the time; it was named on the list afterwards. The endurance findings, that treated animals swam longer, ran further and tolerated heat and low oxygen better, come from rats and mice. No randomised trial of bromantane on human exercise performance could be located, so the ban reflects a regulatory judgement rather than measured athletic benefit. Anyone subject to drug testing should not take it.
Heat and altitude tolerance: two small human experiments, the rest animal work
The actoprotector idea, raising work capacity under stress without raising oxygen consumption, comes mainly from rodent experiments. Two small human studies exist and both come from the former Soviet region. In a 1993 Soviet occupational-medicine experiment, volunteers took a single 250 mg dose before exposure to a heating microclimate of about 50 degrees Celsius combined with a toxic gas, and tolerated it better than on placebo; the report gives no sample size, and its title says carbon monoxide while its own text says carbon dioxide at 300 mg per cubic metre. In a 2014 study of people moving from 1,670 m to 3,750 m, the treatment tested was ladasten combined with metaprote, so the effect of bromantane alone cannot be read out of it. The 250 mg dose is two to five times what people buying bromantane usually take.
The 2006 pilot trial that preceded the Russian approval
The first published clinical study of ladasten was a phase II pilot in patients with psychogenic asthenic disorder, reported in Russian in 2006 by Siuniakov, Grishin, Teleshova, Neznamov and Seredenin at the Zakusov Research Institute of Pharmacology, which developed the drug. It reported that ladasten combined a stimulant and an anxiety-reducing effect, with the stimulant action predominating after a single dose. The published abstract does not state how many patients took part, and the study had no placebo comparison group.
Mechanism of action
Dopamine-synthesis enzymes upregulated in rat brain
In rat brain, bromantane increases expression of the genes for tyrosine hydroxylase and DOPA decarboxylase, the enzymes of dopamine synthesis, and one study reported cytosine demethylation of the tyrosine hydroxylase promoter in rat hypothalamus. The usual reading is that the drug raises the brain's capacity to make dopamine rather than releasing stored dopamine as amphetamines do, though the same rat work attributes the drug's first hours of action to increased dopamine release. None of this has been measured in humans, and the one-month persistence it is offered to explain comes from a 728-patient Russian study that had no placebo comparison.
Atypical CNS stimulant pharmacology
Acts via dopaminergic and possibly serotonergic systems but exact mechanism remains incompletely characterized. Distinct from amphetamines (release/reverse transport), methylphenidate (uptake inhibition), modafinil (uncertain). Atypical profile gives unique stimulant-anxiolytic combination.
Mitochondrial enzyme upregulation
Upregulates mitochondrial enzymes involved in oxidative phosphorylation. Mechanism for actoprotector properties — enhanced cellular energy efficiency under stress without increased oxygen consumption.
Immunomodulation effects
Changes in interferon, IgA and natural killer cell activity have been reported, and bromantan was used in Russia as an immunostimulant. The published work is in laboratory animals; no human immune outcome has been measured.
Possible enzyme induction, not confirmed in any published study
Bromantane is often described as an inducer of the liver enzyme CYP3A4, which would speed the breakdown of drugs cleared by that enzyme. A PubMed search for bromantan or ladasten together with CYP3A4 or cytochrome returns no results, so no published human or laboratory study supporting this could be located. Treat it as an untested possibility rather than an established interaction, and do not rely on it either way when taking other medicines.
Clinical trials
Voznesenskaia TG, Fokina NM, Iakhno NN. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(5 Pt 1):17-26. Published in Russian. Open-label, no placebo or comparator group.
728 patients with psychoautonomic syndrome (91.6% of total sample) across 28 clinical centers in Russia. Diagnosis: asthenia/neurasthenia. Dosage: 50 mg or 100 mg/day Ladasten (bromantane) for 28 days, single morning dose.
Responder rates were 76.0 percent on CGI-Severity and 90.8 percent on CGI-Improvement, with reported falls in fatigue, low energy, irritability, headache and sleep disturbance, and the effect still present one month after treatment stopped. Adverse effects were recorded in 3 percent of patients and 0.8 percent stopped treatment because of them. Because every patient received the drug and none received placebo, none of these numbers can be separated from the natural course of the condition or from expectation. This is the largest published bromantane study.
Siuniakov SA, Grishin SA, Teleshova ES, Neznamov GG, Seredenin SB. Eksp Klin Farmakol. 2006;69(4):10-15. Published in Russian. Phase II pilot run at the Zakusov Research Institute of Pharmacology, which developed the drug.
Patients with psychogenic asthenic disorder. The published abstract does not state how many patients were enrolled, and there was no placebo group.
Ladasten was reported to combine a stimulant effect with an anxiety-reducing effect, with the stimulant action predominating after a single dose, and the authors judged it effective in these patients. Without a placebo group and without a stated sample size, the size of the effect cannot be established. This pilot preceded the 2010 multicentre study.
Anti-doping regulatory record and doping-control detection work, not a study of whether bromantane helps anyone. Key published item: Burnat P, Payen A, Le Brumant-Payen C, Hugon M, Ceppa F. Bromontan, a new doping agent. Lancet. 1997;350(9082):963-964.
Not a study population. Athletes sampled during doping control, beginning with five who tested positive at the 1996 Atlanta Olympics.
Doping-control laboratories detect bromantan and its hydroxylated metabolites in urine well after the drug's effects have gone; the 14-day window usually quoted for it could not be traced to a published human excretion study. It sits on the World Anti-Doping Agency Prohibited List as a non-specified stimulant in class S6.A, prohibited in competition, and has been listed since the late 1990s. Russian athletes who tested positive at Atlanta in 1996 were disqualified, and the Court of Arbitration for Sport then set aside the disqualifications of the two bronze medallists because bromantan was not on the IOC list at the time. Detection and prohibition say nothing about whether the drug improves performance; no randomised human performance trial has been published.